120 related articles for article (PubMed ID: 8474285)
41. Meningococcal disease--some issues in treatment.
Wall RA
J Infect; 2001 Feb; 42(2):87-99. PubMed ID: 11531314
[No Abstract] [Full Text] [Related]
42. Meningococcemia as a model for testing the hypothesis of antisepsis therapies.
Giroir BP
Crit Care Med; 2000 Sep; 28(9 Suppl):S57-9. PubMed ID: 11007199
[TBL] [Abstract][Full Text] [Related]
43. Thwarting a killer.
Dixon JE; Fearneyhough PK; Callen JP
Am J Med; 2006 Apr; 119(4):310-1. PubMed ID: 16564771
[No Abstract] [Full Text] [Related]
44. Meningococcal septicemia presenting as bilateral endophthalmitis.
Chacko E; Filtcroft I; Condon PI
J Cataract Refract Surg; 2005 Feb; 31(2):432-4. PubMed ID: 15767169
[TBL] [Abstract][Full Text] [Related]
45. Looking back on HA-1A.
Quezado ZM; Natanson C; Hoffman WD
Arch Intern Med; 1994 Nov; 154(21):2393. PubMed ID: 7979833
[No Abstract] [Full Text] [Related]
46. [Monoclonal antibodies against endotoxin in septicemia. Marketing or scientific evaluation?].
Waage A
Tidsskr Nor Laegeforen; 1994 Mar; 114(8):951-3. PubMed ID: 8191476
[No Abstract] [Full Text] [Related]
47. New therapies for severe meningococcal disease.
Giroir BP
Lancet; 1998 Feb; 351(9101):526-8. PubMed ID: 9482481
[No Abstract] [Full Text] [Related]
48. The HA-1A saga: the scientific and ethical dilemma of innovative and costly therapies.
Brun-Buisson C
Intensive Care Med; 1994 May; 20(5):314-6. PubMed ID: 7930023
[No Abstract] [Full Text] [Related]
49. Timing therapy for meningococcal infection.
Radetsky M
Pediatr Infect Dis J; 1997 May; 16(5):540-2. PubMed ID: 9154565
[No Abstract] [Full Text] [Related]
50. Monoclonal endotoxin antibody in meningococcal sepsis.
Lorijn RH
Lancet; 1992 Apr; 339(8798):930-1. PubMed ID: 1348320
[No Abstract] [Full Text] [Related]
51. Protein C administration in meningococcal septicaemia.
Bhandari S
Nephrol Dial Transplant; 1998 Sep; 13(9):2421-2. PubMed ID: 9761547
[No Abstract] [Full Text] [Related]
52. [Autolimiting acute meningococcemia].
Núñez MJ; Míguez E; Echániz A; Pereira S; Romero E; Llinares P
Enferm Infecc Microbiol Clin; 1996 Nov; 14(9):571-2. PubMed ID: 9035721
[No Abstract] [Full Text] [Related]
53. [Is it possible to treat infections with non-antimicrobial agents?].
Gómez J; Ruiz-Gómez J; Herrero F
Enferm Infecc Microbiol Clin; 1993 Dec; 11(10):519-21. PubMed ID: 8142499
[No Abstract] [Full Text] [Related]
54. Meningococcal disease: recognition, treatment, and prevention.
Herf C; Nichols J; Fruh S; Holloway B; Anderson CU
Nurse Pract; 1998 Aug; 23(8):30, 33-6, 39-40 passim. PubMed ID: 9718600
[TBL] [Abstract][Full Text] [Related]
55. HA-1A in gram-negative sepsis.
Jennings M
Pharmacoeconomics; 1992 Sep; 2(3):248-9. PubMed ID: 10147118
[No Abstract] [Full Text] [Related]
56. [Meningococcemia during eculizumab treatment].
Rey-Múgica Mde L; Hernando-Real S; Carrero-González P; Queizán-Hernández JA
Enferm Infecc Microbiol Clin; 2013 Jan; 31(1):62. PubMed ID: 22938888
[No Abstract] [Full Text] [Related]
57. Acute meningococcemia.
Sapadin A; Gordon M; Bottone EJ
Mt Sinai J Med; 1997; 64(4-5):353. PubMed ID: 9293739
[No Abstract] [Full Text] [Related]
58. Is HA-1A cost-effective?
Jennings M
Pharmacoeconomics; 1993 Jan; 3(1):84-6. PubMed ID: 10147125
[No Abstract] [Full Text] [Related]
59. Clinical trials of immunotherapy for sepsis.
Cunnion RE
Crit Care Med; 1992 Jun; 20(6):721-3. PubMed ID: 1597020
[No Abstract] [Full Text] [Related]
60. Abdominal pain and fever--an unusual presentation of meningococcemia.
Demeter A; Gelfand MS
Clin Infect Dis; 1999 Jun; 28(6):1327. PubMed ID: 10451180
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
